Literature DB >> 24917748

Single foci prostate cancer: current diagnosis and management.

Ioannis Efthimiou1, Konstadinos Skrepetis1, Elefteria Bournia2.   

Abstract

Diagnosis of small prostate cancer foci is a real challenge for pathologists and urologists as it carries the risk of false positive or negative diagnosis with clinical consequences. Diagnosis of small prostate cancer foci requires a strict methodological approach which includes a search for major and minor features under low and high magnification. Ambiguous cases can be further clarified with the use of basal cell immunomarkers complemented by a positive indicator of malignancy. Despite the new diagnostic armamentarium, a few cases will continue to remain doubtful and might require an appropriate rebiopsy.

Entities:  

Keywords:  Prostate cancer; Single foci

Year:  2013        PMID: 24917748      PMCID: PMC3783292          DOI: 10.1159/000343544

Source DB:  PubMed          Journal:  Curr Urol        ISSN: 1661-7649


  40 in total

Review 1.  Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy").

Authors:  Rodolfo Montironi; Vincenzo Scattoni; Roberta Mazzucchelli; Antonio Lopez-Beltran; David G Bostwick; Francesco Montorsi
Journal:  Eur Urol       Date:  2006-08-10       Impact factor: 20.096

2.  The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme.

Authors:  Vincenzo Scattoni; Marco Raber; Umberto Capitanio; Firas Abdollah; Marco Roscigno; Diego Angiolilli; Carmen Maccagnano; Andrea Gallina; Antonio Saccà; Massimo Freschi; Claudio Doglioni; Patrizio Rigatti; Francesco Montorsi
Journal:  Eur Urol       Date:  2011-07-30       Impact factor: 20.096

3.  Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.

Authors:  L M Boccon-Gibod; O Dumonceau; M Toublanc; V Ravery; L A Boccon-Gibod
Journal:  Eur Urol       Date:  2005-12       Impact factor: 20.096

Review 4.  A clinical dilemma; single prostatic cancer focus in biopsy. Interpretation and management.

Authors:  I Efthimiou; K Skrepetis; E Bournia
Journal:  J BUON       Date:  2010 Jan-Mar       Impact factor: 2.533

5.  False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.

Authors:  Tineke Wolters; Theodorus H van der Kwast; Cornelis J Vissers; Chris H Bangma; Monique Roobol; Fritz H Schröder; Geert J L H van Leenders
Journal:  Am J Surg Pathol       Date:  2010-01       Impact factor: 6.394

6.  Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up.

Authors:  P Thorson; R T Vollmer; C Arcangeli; D W Keetch; P A Humphrey
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

7.  Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies.

Authors:  Robert Abouassaly; Nelly Tan; Ayman Moussa; J Stephen Jones
Journal:  J Urol       Date:  2008-07-17       Impact factor: 7.450

8.  The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.

Authors:  K J Wojno; J I Epstein
Journal:  Am J Surg Pathol       Date:  1995-03       Impact factor: 6.394

9.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

10.  GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.

Authors:  G Kristiansen; F R Fritzsche; K Wassermann; C Jäger; A Tölls; M Lein; C Stephan; K Jung; C Pilarsky; M Dietel; H Moch
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

View more
  2 in total

1.  Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.

Authors:  Ying-Li Lin; Pei-Gen Xie; Li Wang; Jian-Guo Ma
Journal:  Med Sci Monit       Date:  2014-08-05

2.  Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.

Authors:  Wen-Bin Niu; Shi-Liang Gui; Ying-Li Lin; Xing-Li Fu; Jian-Guo Ma; Wen-Ping Li
Journal:  Med Sci Monit       Date:  2014-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.